Carrie K Jones

List of Publications by Year
in descending order

90	4,010	117625	128289
papers	citations	34 h-index	60 g-index

95	95	95	3615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M₅ Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder. Journal of Medicinal Chemistry, 2022, 65, 6273-6286.	6.4	8
2	Partial mGlu5 Negative Allosteric Modulator M-5MPEP Demonstrates Antidepressant-Like Effects on Sleep Without Affecting Cognition or Quantitative EEG. Frontiers in Neuroscience, 2021, 15, 700822.	2.8	5
3	Age and circadian rhythmâ€dependent effects of M ₁ muscarinic acetylcholine receptor positive allosteric modulators and donepezil on sleepâ€wake architecture and arousal. Alzheimer's and Dementia, 2021, 17, .	0.8	0
4	Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Molecular Psychiatry, 2020, 25, 2786-2799.	7.9	28
5	Sexual Dimorphism in Stressâ€induced Hyperthermia in SNAP25Î”3 mice, a mouse model with disabled Gî²î³ regulation of the exocytotic fusion apparatus. European Journal of Neuroscience, 2020, 52, 2815-2826.	2.6	5
6	Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates. Neuropsychopharmacology, 2020, 45, 2219-2228.	5.4	13
7	Phenotypic profiling of <scp>mGlu₇</scp> knockout mice reveals new implications for neurodevelopmental disorders. Genes, Brain and Behavior, 2020, 19, e12654.	2.2	25
8	Acetylcholine Muscarinic M4 Receptors as a Therapeutic Target for Alcohol Use Disorder: Converging Evidence From Humans and Rodents. Biological Psychiatry, 2020, 88, 898-909.	1.3	24
9	The Effects of the M 1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0486846 on Cognitive Performance in Aged Nonhuman Primates. FASEB Journal, 2020, 34, 1-1.	0.5	0
10	Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders. Advances in Pharmacology, 2019, 86, 153-196.	2.0	12
11	Acute Negative Allosteric Modulation of M₅ Muscarinic Acetylcholine Receptors Inhibits Oxycodone Self-Administration and Cue-Induced Reactivity with No Effect on Antinociception. ACS Chemical Neuroscience, 2019, 10, 3740-3750.	3.5	27
12	The Role of Estrogen in Brain and Cognitive Aging. Neurotherapeutics, 2019, 16, 649-665.	4.4	98
13	SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2224-2228.	2.2	4
14	VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1714-1718.	2.2	6
15	Disabling the Gî²î³-SNARE interaction disrupts GPCR-mediated presynaptic inhibition, leading to physiological and behavioral phenotypes. Science Signaling, 2019, 12, .	3.6	33
16	In Vitro to in Vivo Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery. ACS Pharmacology and Translational Science, 2019, 2, 442-452.	4.9	7
17	Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 47-50.	2.2	5
18	The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 342-346.	2.2	6

#	Article	IF	Citations
19	Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinsonâ€™s Disease. ACS Medicinal Chemistry Letters, 2019, 10, 255-260.	2.8	17
20	Analgesic Effects of the GIRK Activator, VU0466551, Alone and in Combination with Morphine in Acute and Persistent Pain Models. ACS Chemical Neuroscience, 2019, 10, 1294-1299.	3.5	15
21	Discovery, Structureâ€“Activity Relationship, and Biological Characterization of a Novel Series of 6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-benzo[d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu₄). Journal of Medicinal Chemistry, 2019, 62, 342-358.	6.4	16
22	Discovery and Optimization of Potent and CNS Penetrant M₅-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold. ACS Chemical Neuroscience, 2018, 9, 1572-1581.	3.5	13
23	Muscarinic M5 receptors modulate ethanol seeking in rats. Neuropsychopharmacology, 2018, 43, 1510-1517.	5.4	33
24	A Novel M₁ PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity. ACS Chemical Neuroscience, 2018, 9, 2274-2285.	3.5	43
25	Total RNA Sequencing of Rett Syndrome Autopsy Samples Identifies the M₄ Muscarinic Receptor as a Novel Therapeutic Target. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 291-300.	2.5	29
26	Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology, 2018, 128, 492-502.	4.1	35
27	Selective inhibition of M₅ muscarinic acetylcholine receptors attenuates cocaine selfâ€administration in rats. Addiction Biology, 2018, 23, 1106-1116.	2.6	29
28	Classics in Chemical Neuroscience: Xanomeline. ACS Chemical Neuroscience, 2017, 8, 435-443.	3.5	39
29	Continued optimization of the M 5 NAM ML375: Discovery of VU6008667, an M 5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1356-1359.	2.2	23
30	Optimization of M 4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2296-2301.	2.2	17
31	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2990-2995.	2.2	16
32	OCD candidate gene SLC1A1 /EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 5719-5724.	7.1	46
33	Diverse Effects on M₁ Signaling and Adverse Effect Liability within a Series of M₁ Ago-PAMs. ACS Chemical Neuroscience, 2017, 8, 866-883.	3.5	44
34	Discovery of VU0467485/AZ13713945: An M₄ PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia. ACS Medicinal Chemistry Letters, 2017, 8, 233-238.	2.8	43
35	Challenges in the development of an M 4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 171-175.	2.2	32
36	Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5179-5184.	2.2	17

#	Article	IF	Citations
37	Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4858-4866.	2.2	8
38	Discovery of VU6005649, a CNS Penetrant mGlu_{7/8} Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines. ACS Medicinal Chemistry Letters, 2017, 8, 1110-1115.	2.8	28
39	Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu₃ NAMs. ACS Medicinal Chemistry Letters, 2017, 8, 925-930.	2.8	38
40	mGlu ₇ potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Science Translational Medicine, 2017, 9, .	12.4	55
41	Design and Synthesis of mGlu₂ NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. ACS Medicinal Chemistry Letters, 2017, 8, 919-924.	2.8	33
42	Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron, 2017, 96, 1358-1372.e4.	8.1	43
43	Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2915-2919.	2.2	3
44	Discovery and optimization of a novel series of highly CNS penetrant M 4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3- d]pyrimidine core. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3029-3033.	2.2	22
45	Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4487-4491.	2.2	15
46	Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release. Neuron, 2016, 91, 1244-1252.	8.1	110
47	Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M₁ PAM VU6004256. ACS Chemical Neuroscience, 2016, 7, 1706-1716.	3.5	39
48	Anatomical localization of Ca_v3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys. Journal of Neurophysiology, 2016, 115, 470-485.	1.8	23
49	N-Alkylpyrido[1â€²,2â€²:1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1894-1900.	2.2	9
50	mGlu₅positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Human Molecular Genetics, 2016, 25, 1990-2004.	2.9	48
51	An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia. Neuropsychopharmacology, 2016, 41, 2052-2061.	5.4	60
52	Preliminary investigation of 6,7-dihydropyrazolo[1,5- a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 429-434.	2.2	7
53	State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 â€“ Relation to antipsychotic-like drug effects. Neuropharmacology, 2016, 102, 244-253.	4.1	23
54	Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects. Neuropsychopharmacology, 2016, 41, 1166-1178.	5.4	33

#	Article	IF	Citations
55	Discovery of VU0409551/JNJ-46778212: An mGlu₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. ACS Medicinal Chemistry Letters, 2015, 6, 716-720.	2.8	41
56	VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2015, 356, 123-136.	2.5	41
57	Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14078-14083.	7.1	41
58	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1310-1317.	2.2	9
59	A Rodent Model of Traumatic Stress Induces Lasting Sleep and Quantitative Electroencephalographic Disturbances. ACS Chemical Neuroscience, 2015, 6, 485-493.	3.5	45
60	Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. Neuropsychopharmacology, 2015, 40, 755-765.	5.4	40
61	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3515-3519.	2.2	7
62	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology, 2015, 95, 121-129.	4.1	46
63	Biased mGlu 5 -Positive Allosteric Modulators Provide InÂVivo Efficacy without Potentiating mGlu 5 Modulation of NMDAR Currents. Neuron, 2015, 86, 1029-1040.	8.1	121
64	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5115-5120.	2.2	5
65	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents. Journal of Medicinal Chemistry, 2015, 58, 7485-7500.	6.4	62
66	Selective Antagonism of mGlu5 Alters Sleepâ€wake and Spectral EEG and Ameliorates Behavioral Abnormalities in a Rodent Model of Traumatic Stress. FASEB Journal, 2015, 29, 615.8.	0.5	1
67	Phospholipase D Facilitates Efficient Entry of Influenza Virus, Allowing Escape from Innate Immune Inhibition. Journal of Biological Chemistry, 2014, 289, 25405-25417.	3.4	52
68	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3641-3646.	2.2	7
69	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1062-1066.	2.2	6
70	Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: Development of a potent and CNS penetrant [3.1.0]-based lead. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1067-1070.	2.2	8
71	Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4Receptor within VivoActivity. ACS Medicinal Chemistry Letters, 2014, 5, 1060-1064.	2.8	16
72	Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100. Neuropsychopharmacology, 2014, 39, 1578-1593.	5.4	91

#	Article	IF	Citations
73	Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3307-3314.	2.2	9
74	Selective Activation of M₄ Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents. ACS Chemical Neuroscience, 2014, 5, 920-942.	3.5	116
75	M4 muscarinic acetylcholine receptor modulation of associative learning and behavioral flexibility in a novel touchscreen cognitive assessment (845.8). FASEB Journal, 2014, 28, 845.8.	0.5	0
76	Effects of M1 and M4 muscarinic acetylcholine receptor positive allosteric modulators on sleep and cognition in rodents. FASEB Journal, 2013, 27, 661.8.	0.5	0
77	The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 404-421.	2.5	95
78	Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia. Neuropsychopharmacology, 2012, 37, 16-42.	5.4	177
79	Muscarinic Receptor Pharmacology and Circuitry for the Modulation of Cognition. Handbook of Experimental Pharmacology, 2012, , 121-166.	1.8	92
80	Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. Discovery Medicine, 2012, 14, 413-20.	0.5	36
81	Discovery, Synthesis, and Structureâ€"Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄) with Oral Efficacy in an Antiparkinsonian Animal Model. Journal of Medicinal Chemistry, 2011, 54, 7639-7647.	6.4	52
82	Discovery and Characterization of Novel Subtype-Selective Allosteric Agonists for the Investigation of M₁ Receptor Function in the Central Nervous System. ACS Chemical Neuroscience, 2010, 1, 104-121.	3.5	88
83	Discovery of the First Highly M5-Preferring Muscarinic Acetylcholine Receptor Ligand, an M5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins. Journal of Medicinal Chemistry, 2009, 52, 3445-3448.	6.4	92
84	Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharmacological Sciences, 2009, 30, 25-31.	8.7	325
85	Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends in Pharmacological Sciences, 2009, 30, 148-155.	8.7	258
86	Novel Selective Allosteric Activator of the M₁Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats. Journal of Neuroscience, 2008, 28, 10422-10433.	3.6	219
87	Centrally Active Allosteric Potentiators of the M₄ Muscarinic Acetylcholine Receptor Reverse Amphetamine-Induced Hyperlocomotor Activity in Rats. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 941-953.	2.5	177
88	Characterization of novel selective positive allosteric modulators (PAMS) of the M4 muscarinic acetylcholine receptor (mAChR). FASEB Journal, 2008, 22, 714.2.	0.5	0
89	Pharmacologic Interactions between the Muscarinic Cholinergic and Dopaminergic Systems in the Modulation of Prepulse Inhibition in Rats. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 1055-1063.	2.5	80
90	Efficacy of Duloxetine, a Potent and Balanced Serotonergic and Noradrenergic Reuptake Inhibitor, in Inflammatory and Acute Pain Models in Rodents. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 726-732.	2.5	140